**Regular Article**

**In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil**

Hiroki Higashi, Nao Watanabe, Rika Tamura, and Masato Taguchi*

Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama; 2630 Sugitani, Toyama 930–0194, Japan.

Received March 30, 2017; accepted May 8, 2017

Tadalafil and sildenafil are selective inhibitors of phosphodiesterase type 5, showing marked pharmacokinetic variability in patients with pulmonary arterial hypertension. It has been reported that sildenafil is a substrate for P-glycoprotein (P-gp), but whether tadalafil is a substrate for P-gp remains to be determined.

The objective of the present study was to elucidate whether tadalafil is a substrate for P-gp. Transcellular transport of sildenafil and tadalafil (5 μM each) was examined using renal epithelial LLC-PK1 and P-gp-expressing LLC-GA5-COL150 cell monolayers. The efflux ratio of the basal to apical (B to A) transport of sildenafil to the A to B transport after 120-min incubation in LLC-GA5-COL150 cells (1.52) was significantly higher than that in LLC-PK1 cells (0.71). The efflux ratio of the B to A transport of tadalafil to the A to B transport after 120-min incubation in LLC-GA5-COL150 cells (10.4) was significantly higher than that in LLC-PK1 cells (1.23). In LLC-GA5-COL150 cell monolayers, the $V_{\text{max}}$ and $K_{\text{m}}$ values of sildenafil transport calculated from a modified Michaelis–Menten equation were $101 \pm 64$ pmol/min/cm$^2$ and $112 \pm 47 \mu$M, respectively. On the other hand, those of tadalafil transport were $13.6 \pm 8.4$ pmol/min/cm$^2$ and $22.7 \pm 9.3 \mu$M, respectively. In the presence of a P-gp inhibitor (PSC833), the B to A transport of tadalafil was decreased by 28.6% in LLC-GA5-COL150 cells, and the A to B transport of tadalafil was 6.59-fold greater than that in its absence. These results indicate that tadalafil is a substrate for P-gp.

**Key words** tadalafil; sildenafil; P-glycoprotein

Tadalafil and sildenafil are potent and selective inhibitors of cyclic GMP-specific phosphodiesterase type 5 (PDE5) in vascular smooth muscle. These drugs have been used as treatments not only for erectile dysfunction, but also for pulmonary arterial hypertension (PAH). Sildenafil has a short half-life of about 3–5 h, whereas tadalafil has a long half-life of about 17.5 h. Due to its long half-life, tadalafil has the advantage of once-a-day dosing compared with 3-times-a-day dosing for sildenafil. For patient convenience and compliance, the transition from sildenafil to tadalafil has been tried in stable patients with PAH. However, it is necessary to understand the difference between the pharmacokinetics of the two drugs for their safe use.

Sildenafil is eliminated predominantly by hepatic metabolism and converted to an active metabolite, N-desmethyl sildenafil. In healthy men, metabolites are predominantly excreted into the feces (73–83%) and to a lesser extent urine (6–15%) after an oral dose. In our previous study, we confirmed that the N-demethylation of sildenafil was mediated by both CYP3A4 and CYP3A5 isozymes. That is, the Michaelis–Menten constant ($K_{\text{m}}$) values for CYP3A4 and CYP3A5 isozymes were estimated to be 27.7±7.5 and 17.4±3.2 μM, respectively, and the maximum transport rate ($V_{\text{max}}$) values were 30.7±11.3 and 18.9±6.1 pmol/min/pmol P450, respectively. In addition, Choi and Song reported that sildenafil was a substrate for P-glycoprotein (P-gp). That is, the transcellular transport of sildenafil in P-gp-expressing Madin–Darby canine kidney II (MDCKII)-multidrug resistance protein 1 (MDR1) cells in a basal to apical (B to A) direction was 4.87-fold greater than that from A to B. They proposed that P-gp might be the underlying mechanism related to the low and variable oral bioavailability of sildenafil.

**Key points**

- Tadalafil and sildenafil are selective inhibitors of PDE5.
- Tadalafil is eliminated predominantly by hepatic metabolism.
- Sildenafil is eliminated mainly by hepatic metabolism and converted to an active metabolite, N-desmethyl sildenafil.
- In healthy men, sildenafil metabolites are predominantly excreted into the feces (73–83%) and to a lesser extent urine (6–15%) after oral administration.
- In our previous study, we confirmed that the N-demethylation of sildenafil was mediated by both CYP3A4 and CYP3A5 isozymes. The $K_{\text{m}}$ values for CYP3A4 and CYP3A5 isozymes were estimated to be 27.7±7.5 and 17.4±3.2 μM, respectively, and the $V_{\text{max}}$ values were 30.7±11.3 and 18.9±6.1 pmol/min/pmol P450, respectively.
- In addition, Choi and Song reported that sildenafil was a substrate for P-gp.

**MATERIALS AND METHODS**

**Reagents** Sildenafil and tadalafil were purchased from To-
ronto Research Chemicals (North York, ON, Canada). PSC833 was purchased from AdooQ BioScience (Irvine, CA, U.S.A.). [14C]-Mannitol (0.1 mCi/mL) was purchased from American Radiolabeled Chemicals (St. Louis, MO, U.S.A.). All other chemicals and solvents were of the highest purity available.

**Cell Lines and Cell Culture** LLC-PK1 cells were purchased from the American Type Culture Collection (Manassas, VA, U.S.A.). LLC-GA5-COL150 cells were purchased from the Riken Biobasecenter (Tsukuba, Japan).

LLC-PK1 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 1% MEM nonessential amino acids, 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified atmosphere with 5% CO2/95% air at 37°C. LLC-GA5-COL150 cells were cultured under the same conditions with the exception of the addition of 150 ng/mL of colchicine, which was added to the medium to maintain P-gp expression. The medium was changed every 2 or 3 days, and when the cells reached 70–80% confluence, they were subcultured using a 0.02% ethylenediaminetetraacetic acid (EDTA)/0.05% trypsin solution. The cells were seeded at a density of 5 x 10^4 cells/cm^2 on a 0.4-µm pore size in a cell culture insert (BD Bioscience, Bedford, MA, U.S.A.). The seeded LLC-PK1 and LLC-GA5-COL150 cells were grown for 6 or 7 days.

The maturity of cell monolayers was evaluated prior to transport experiments by measuring transepithelial electrical resistance (TEER). TEER was measured using a Millicell-ERS resistance system (Millipore, Bedford, MA, U.S.A.). LLC-PK1 cell monolayers whose TEER was above 40 Ω cm^2 were used to assess the transepithelial transport. LLC-GA5-COL150 cell monolayers whose TEER was above 100 Ω cm^2 were used.

**Transcellular Transport of Sildenafil and Tadalafil**

The transport of sildenafil or tadalafil (5 µM each) across LLC-PK1 and LLC-GA5-COL150 cell monolayers was examined. Also, the transport of sildenafil (3–100 µM) or tadalafil (1–100 µM) across LLC-GA5-COL150 cell monolayers used for kinetic analysis was examined. The composition of the incubation medium was as follows: 123 mM NaCl, 4.8 mM KCl, 5.6 mM d-glucose, 1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1 mM sodium pyruvate, and 25 mM N2-hydroxyethylpiperazine- N’-2-ethanesulfonic acid (HEPES) (pH 7.4). Cells were pre-incubated with the incubation medium for 30 min at 37°C. The apical or basal side was replaced with the incubation medium containing sildenafil or tadalafil after pre-incubation. An 80-µL (apical side) or a 150-µL (basal side) aliquot of the medium was collected after 30, 60, 90, or 120 min from the compartment opposite to that in which sildenafil or tadalafil was added. To compensate for the volume sampled, an 80-µL (apical side) or a 150-µL (basal side) aliquot of incubation medium pre-warmed at 37°C was added immediately after each sampling. The concentrations of sildenafil and tadalafil in each sample were determined by LC-MS/MS and HPLC methods, respectively.

**Kinetic Analysis**

The kinetic parameters of the membrane permeation of sildenafil or tadalafil in LLC-GA5-COL150 cells were estimated, mannitol was used as a paracellular marker. That is, mannitol (1–100 µM) contained a fixed amount of [14C]-mannitol, and the radioactivity of [14C]-mannitol was measured by a scintillation counter for 3 min. The amount of transepidermal transport of sildenafil or tadalafil in the B to A direction was calculated by subtracting the amount of mannitol.

**Effect of the P-gp Inhibitor on the Transport of Sildenafil and Tadalafil in LLC-GA5-COL150 Cells**

To determine the involvement of P-gp on the transport of sildenafil and tadalafil across LLC-GA5-COL150 cell monolayers, the potential inhibition of transport was examined in the presence or absence of P-gp inhibitor (PSC833). In brief, cells were pre-incubated with the incubation medium containing 2 µM PSC833 and sildenafil or tadalafil (5 µM each) for 30 min at 37°C. An 80-µL (apical side) or a 150-µL (basal side) aliquot of the medium was collected after 30 min from the compartment opposite to that in which sildenafil or tadalafil was added. To compensate for the volume sampled, an 80-µL (apical side) or a 150-µL (basal side) aliquot of incubation medium was added immediately after each sampling. The concentrations of sildenafil and tadalafil in each sample were determined by LC-MS/MS and HPLC methods, respectively.

**HPLC Analysis**

Concentrations of tadalafil were determined by a reversed-phase HPLC method. The total aliquot of the sample was mixed with three times the amount of methanol to remove proteins and centrifuged at 2000 x g for 10 min at 4°C, and 50 µL of its supernatant was injected into the HPLC system. The mobile phase was 0.1% trifluoroacetic acid (TFA) and acetonitrile (60:40, v/v). The flow rate was 1.0 mL/min, and column temperature was 40°C. The HPLC system consisted of a Shimadzu LC-10ATvp (Kyoto, Japan), a COSMOSIL C8 reverse-phase column (4.6 x 150 mm), and a model RF-20A fluorecence detector (Shimadzu). The detection wavelengths were 275 nm (λex) and 335 nm (λem). The limit of quantification for tadalafil was 1 nm.

**LC-MS/MS Analysis**

Concentrations of sildenafil were determined by the LC-MS/MS method. The total aliquot of the sample was mixed with three times the amount of methanol containing diazepam as an internal standard and centrifuged at 2000 x g for 10 min at 4°C, and 20 µL of its supernatant was injected into the LC-MS/MS system. The mobile phase was 10 mM ammonium formate (with 0.1% formic acid) and acetonitrile (20:80, v/v). The flow rate was 100 µL/min, and the column temperature was 40°C. LC-MS/MS analysis was carried out in a Thermo Fisher Accela LC system with a COSMOSIL3C18 packed column of 2.5 x 18-mm-2 (0.5 x 50 nm) (Thermo Fisher Scientific) coupled to an LTQ-Orbitrap XL ETD system (Thermo Fisher Scientific). The cone voltage was 35 V and collision energy was 30 V. Mass spectra were recorded by electrospray ionization in the positive mode. The detector was operated in selected reaction monitoring (SRM) mode using the transitions of sildenafil at m/z 475.4→283.0 and diazepam at m/z 285.0→193.0, respectively. The peak areas were calculated using Qualbrowser software (Thermo Fisher Scientific). The limit of quantification for sildenafil was 10 nm.

**Kinetic Analysis**

The kinetic parameters for the transport of sildenafil and tadalafil were estimated using a modified Michaelis–Menten equation (Eq. 1):

\[
V = \frac{V_{max} \cdot S}{K_m + S} + K \cdot S
\]

where \(V\) is the velocity of the reaction, \(S\) is the substrate concentration, \(V_{max}\) is the maximum transport rate, \(K_m\) is the Michaelis–Menten constant, respectively, and \(K\) represents the
Statistical Analysis

The significance of the differences between the two groups was evaluated using Student’s t-test if the variance of the group was similar. If this was not the case, the Mann–Whitney U-test was applied. 

$p<0.05$ was considered significant. Data are expressed as the mean±standard error (S.E.)

RESULTS

To elucidate whether tadalafil is a substrate for P-gp, the transcellular transport of sildenafil and tadalafil (5 µM each) was conducted using LLC-PK₁ and LLC-GA5-COL150 cell monolayers (Figs. 1, 2). Because it has been reported that sildenafil is a substrate for P-gp,

$tadafila{l} transport was clearer than that of sildenafil (Fig. 2). The efflux ratio of the B to A transport of tadalafil to the A to B transport after 120-min incubation in LLC-GA5-COL150 cells (1.52) was significantly higher than that in LLC-PK₁ cells (0.71) (Table 1). The efflux ratio of the B to A transport of tadalafil to the A to B transport after 120-min incubation in LLC-GA5-COL150 cells (10.4) was significantly higher than that in LLC-PK₁ cells (1.23) (Table 1).

To evaluate the transport properties of tadalafil, we conducted kinetic analysis of the transport of sildenafil and tadalafil using P-gp-expressing LLC-GA5-COL150
PK nafil and tadalafil were compared using renal epithelial LLC-substrate for P-gp, transcellular transport properties of sildenafil, and the efflux transport of tadalafil is a substrate for P-gp. Because sildenafil is a known substrate of P-gp, such as Caco-2 cells, was asymmetrical. Therefore, we could not conclude that tadalafil is a substrate for P-gp based solely on the efflux ratio (Table 2) or direction selectivity of the transcellular transport (Fig. 2). We then conducted the transport experiment using PSC833, a specific inhibitor of P-gp, in LLC-GA5-COL150 cells (Fig. 4). In the presence of PSC833, the B to A transport of sildenafil and tadalafil was decreased by 19.0 and 28.6%, respectively, and the A to B transport of tadalafil was decreased by 28.6% in LLC-PK cells. These results revealed that tadalafil is a substrate for P-gp as well as sildenafil.

**DISCUSSION**

The objective of the present study was to elucidate whether tadalafil is a substrate for P-gp. Because sildenafil is a known substrate of P-gp, transcellular transport properties of sildenafil and tadalafil were compared using renal epithelial LLC-PK, and P-gp-expressing LLC-GA5-COL150 cell monolayers (Fig. 3). The B to A transport of sildenafil and tadalafil was slight, but clearly saturable over the tested concentration range, suggesting the involvement of P-gp-mediated efflux (Fig. 3). The kinetic parameters of sildenafil transport with the $V_{\text{max}}$ and $K_m$ values calculated from the modified Michaelis–Menten equation were $101 \pm 64 \mu\text{mol/min/cm}^2$ and $112 \pm 47 \mu\text{M}$, respectively, and the $K_v$ value was negligible (less than 0.01 $\mu\text{L/min/cm}^2$) (Table 2). The kinetic parameters of tadalafil transport with the $V_{\text{max}}$, $K_m$, and $V$ values were $13.6 \pm 4.8 \mu\text{mol/min/cm}^2$, $22.7 \pm 9.3 \mu\text{M}$, and $0.062 \pm 0.035 \mu\text{L/min/cm}^2$, respectively. These results suggest that tadalafil had a higher affinity for P-gp as compared with sildenafil (Table 2). The lower $K_m$ value of tadalafil transport may support the finding that the direction selectivity of tadalafil transport was clearer than that of sildenafil at the concentration of 5 $\mu\text{M}$ each (Fig. 2). Eadie–Hofstee plot analysis suggested that no efflux transporters other than P-gp were involved (Fig. 3).

It was reported that P-gp-mediated efflux observed during absorptive and secretory transport via polar cell membranes, such as Caco-2 cells, was asymmetrical. Therefore, we could not conclude that tadalafil is a substrate for P-gp based solely on the efflux ratio (Table 2) or direction selectivity of the transcellular transport (Fig. 2). We then conducted the transport experiment using PSC833, a specific inhibitor of P-gp, in LLC-GA5-COL150 cells (Fig. 4). In the presence of PSC833, the B to A transport of sildenafil and tadalafil was decreased by 19.0 and 28.6%, respectively, and the A to B transport was 3.33- and 6.59-fold greater than in its absence, respectively. In the B to A direction, the effect of PSC833 on the transport of the two drugs was not marked, but it was noticeable in the A to B direction (Fig. 4). These results reveal that tadalafil is a substrate for P-gp as well as sildenafil.

| Table 2. Kinetic Parameters for the Transport of Sildenafil and Tadalafil in LLC-GA5-COL150 Cell Monolayers |
|--------------------------------------------------|-----------------|
| Sildenafil                                      | Tadalafil       |
| $V_{\text{max}}$ (pmol/min/cm$^2$)              | 101 ± 64        |
| $K_m$ ($\mu\text{M}$)                           | 112 ± 47        |
| $K$ ($\mu\text{L/min/cm}^2$)                    | <0.01           |

The kinetic parameters of sildenafil and tadalafil were calculated from the modified Michaelis–Menten equation. Values are expressed as the mean±S.E. (n=6–13).
Michaelis–Menten equation was 50.4 $\mu$M.\textsuperscript{8} This parameter is different from that for sildenafil in the present study (Table 2), but this may be due to the difficulty experienced in the sample solubilization or precipitation control of poorly water-soluble drugs. That is, it is difficult to prepare high (>100 $\mu$M) concentration solutions of tadalafil or sildenafil in water containing less than 1% organic solvent. However, because the direction selectivity of tadalafil transport by P-gp was more significant than that of sildenafil in the present study (Fig. 2), P-gp is also likely to be involved in the mechanisms for the intestinal absorption of tadalafil.

Watkins\textsuperscript{14} proposed that P-gp may be a cause of increased drug metabolism in the small intestine. That is, P-gp may function to prolong the duration of absorption and this might increase the duration of exposure of the drug to the enzyme within the enterocytes and, hence, the extent of metabolism. The author suggested that the functions of CYP3A4 and P-gp might not be additive but synergistic in limiting the oral bioavailability of substrates.\textsuperscript{14} Several studies have suggested that cyclosporine undergoes significant metabolism in the small intestine after oral administration.\textsuperscript{15,16} For example, Kolars et al.\textsuperscript{15} demonstrated the intestinal first-pass metabolism of cyclosporine in two patients during the anhepatic phase of liver transplantation. That is, cyclosporine was administered into the distal duodenum using an enteric feeding tube, and blood samples were drawn from the portal vein periodically until the transplanted liver was reperfused. The authors found that cyclosporine metabolites accounted for 25 and 51%, respectively, of the total identifiable cyclosporine in portal blood from the two patients.\textsuperscript{15}

Lee et al.\textsuperscript{17} investigated the pharmacokinetics of oral and intravenous tadalafil in experimental hyperlipidemia rats. After oral administration, the $C_{\text{max}}$ of tadalafil in hyperlipidemia rats was 5.91-fold higher than that in control rats, and area under the curve (AUC) was 11.9-fold higher in hyperlipidemia rats as compared with control rats. The authors also demonstrated that the absolute oral bioavailability of tadalafil in control rats was 20.5%, whereas that in hyperlipidemia rats was elevated to 115%. These findings suggest that tadalafil was originally well-absorbed from the gut lumen, but some function for influencing first-pass metabolism was impaired in hyperlipidemia rats.\textsuperscript{7} Considering the fact that tadalafil is a drug with low hepatic extraction in humans,\textsuperscript{4} the impaired metabolism of tadalafil in the small intestine may be the cause of the increased oral bioavailability in hyperlipidemia rats.

In the present study, we demonstrated that both sildenafil and tadalafil are substrates for P-gp. On the other hand, it was recently reported that tadalafil but not sildenafil had an effect to induce $ABCBI$ (P-gp) mRNA expression in LS180 cells.\textsuperscript{18} That is, $ABCBI$ mRNA expression after 4-d tadalafil exposure was approximately 4-fold higher than that of the control, whereas sildenafil had no effect on $ABCBI$ mRNA expression.\textsuperscript{18} Therefore, sildenafil and tadalafil may have different drug interaction profiles, although the two drugs are similar in that both are substrates for P-gp. It has also been suggested that dose linearity of the two drugs are different in healthy subjects.\textsuperscript{14,34} That is, statistical evidence of non-proportionality in $C_{\text{max}}$ and AUC of sildenafil was found over the dose range of 25–200 mg.\textsuperscript{31} On the other hand, the dose-normalized AUC values of tadalafil were almost constant across the 8-fold range (2.5–20 mg).\textsuperscript{4} To understand the clinical contribution of P-gp to the intestinal absorption of the two drugs, further studies are warranted.

In conclusion, we demonstrated for the first time that tadalafil is a substrate for P-gp. The present study may promote understanding of not only the transport properties of tadalafil but also one possible cause of variability in its pharmacokinetics.

Acknowledgment This work was supported in part by JSPS KAKENHI Grant number 15K08091.

Conflict of Interest The authors declare no conflict of interest.

REFERENCES

1) Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol., 44, 1488–1496 (2004).
2) Lewis GD, Semigran MJ. Type 5 phosphodiesterase inhibition in
heart failure and pulmonary hypertension. *Curr. Heart Fail. Rep.*, 1, 183–189 (2004).

3) Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. *Br. J. Clin. Pharmacol.*, 53 (Suppl. 1), S5–12S (2002).

4) Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. *Br. J. Clin. Pharmacol.*, 53 (Suppl. 1), 5S–12S (2002).

5) Shlobin OA, Brown AW, Weir N, Ahmad S, Lemma M, Nathan SD. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. *Lung*, 190, 573–578 (2012).

6) MUirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. *Br. J. Clin. Pharmacol.*, 53 (Suppl. 1), 13S–20S (2002).

7) Takahiro R, Nakamura S, Kohno H, Yoshimura N, Nakamura T, Ozawa S, Hirono K, Ichida F, Taguchi M. Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil \(\text{N}\)-demethylation and tadalafil demethylation. *Biol. Pharm. Bull.*, 38, 58–65 (2015).

8) Choi MK, Song IS. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. *J. Pharm. Pharmacol.*, 64, 1074–1083 (2012).

9) Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. *J. Clin. Pharmacol.*, 45, 987–1003 (2005).

10) Kohno H, Ichida F, Hirono K, Ozawa S, Yoshimura N, Nakamura T, Akita C, Ishida K, Taguchi M. Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. *Ther. Drug Monit.*, 36, 576–583 (2014).

11) Tahara K, Kagawa Y, Takaai M, Taguchi M, Hashimoto Y. Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GAS-COL150 cells, but not in renal epithelial LLC-PK1 Cells. *Drug Metab. Pharmacokinet.*, 23, 340–346 (2008).

12) Wang Y, Wang J, Cui Y, Fawcett JP, Gu J. Liquid chromatographic-tandem mass spectrometric method for the quantitation of sildenafil in human plasma. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.*, 828, 118–121 (2005).

13) Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. *Pharm. Res.*, 20, 1200–1209 (2003).

14) Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. *Adv. Drug Deliv. Rev.*, 27, 161–170 (1997).

15) Kolars JC, Awni WM, Merzon RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. *Lancet*, 338, 1488–1490 (1991).

16) Wu CY, Benet LZ, Henry MF, Gupta SK, Rowland M, Gomez DV, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. *Clin. Pharmacol. Ther.*, 58, 492–497 (1995).

17) Lee JH, Oh JH, Lee YJ. Effects of experimental hyperlipidemia on the pharmacokinetics of tadalafil in rats. *J. Pharm. Pharmacol.*, 15, 528–537 (2012).

18) Weiss J, Theile D, Spalvīz A, Burhene J, Riedel KD, Haefeli WE. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. *Biochem. Pharmacol.*, 85, 265–273 (2013).